Evaluation of medication efficacy and safety is an essential guarantee to successful therapeutic outcome in public health practices. However, larger distribution chain supply in developing countries such as Cameroon is often challenged by counterfeit drugs, poor manufacturing, storage and degradation leading to health and patient adverse consequences. Yet, access to supply chain management in strengthening ARVs quality assurance and outcomes remains poorly documented. More than 53,000 patients have been enrolled on free ARVs medications, but little is documented on quality assurance and validity of safety for affected populations along the supply chain management since 2008.
The cross sectional study was conducted in ARVs distribution units and centers in central, littoral and south west regions of Cameroon. ARVs drugs samples included Nevirapine, Efavirenz, and fixed dose combinations of Zidovudine + Lamivudine, Lamivudine + Stavudine and Zidovudine + Lamivudine + Nevirapine. Drugs packaging and labeling was assessed and galenic assays were performed at National Laboratory of quality Control of Medications and Expertise (LANACOME), Yaoundé, Cameroon.
The study covered 16 structures located in eight different towns including the central ARVs store, two regional pharmaceutical procurement centers and thirteen HIV approved treatment centers and management units. A total of 35 ARVs products were collected. Only eight ARVs drugs containing Lamivudine and Stavudine presented with white stains on tablets, however these drugs were standard for all other tests performed. The others 28 ARVs products were standards to all assays performed.
We concluded that ARVs drugs freely accessible and distributed to PLWHA are of good quality in Cameroon. However, with the increase number of patients under HAART since 2013, adoption of “Test and Treat” approach to reach the 90-90-90 goals and with the implementation of new national antiretroviral regimen guidelines and molecules such as boosted protease inhibitors, continuous quality control and assurance surveillance, monitoring and evaluation is recommended. Assessment of quality of formulations that are more susceptible to degradation such as pediatric formulations for averting the rising multidrug resistance trend is also desired.
Fayorsey RN, Saito S, Cartser RJ, Gusmao E, Frederix K. Decentralization of pediatric HIV care and treatment in five sub-saharan african countries. J Acquir Immun Defic Syndr. 2013;62:e124–30. CrossRef
Beker LG, Venter F, Cohen K, Goemare E, Van Cutsem G, Boulle A, Wood R. Provision of antiretroviral therapy in South Africa: the nuts and bolts. Antiretrovir Ther. 2014;19(Suppl 3):105–16. CrossRef
Hoen ET. Assuring access to quality antiretroviral medicines: the WHO prequalification of medicines program and access to HIV treatment. Cad Saúde Pública. 2014;30(5):908–9. CrossRef
Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and counterfeit medical products; Board on Global Health; Institute of Medicine. In: Buckley GJ, Gostin LO, editors. Countering the problem of falsified and substandard drugs. Washington: National Academies Press; 2013.
The effects of falsified and substandard drugs. https://www.ncbi.nlm.nih.gov/books/NBK202526/. Accessed 12 Oct 2016.
Desale A, Taye B, Belay G, Nigatu A. Assessment of laboratory logistics management information system practice for HIV/AIDS and tuberculosis laboratory commodities in selected public health facilities in Addis Ababa, Ethiopia. Pan Afr Med J. 2013;8(15):46.
Windisch R, Waiswa P, Neuhann F, Scheibe F, de Savigny D. Scaling up antiretroviral therapy in Uganda: using supply chain management to appraise health systems strengthening. Glob Health. 2011;1(7):25. CrossRef
Ondari C, Maponga C. The quality of antimalarials. A study in selected African countries. Geneva: WHO; 2003.
World Health Organization Regional Office for Africa. Medicines regulatory authorities: current status and the way forward. Report of the regional director. ARF/RC/56/11; 2006.
James S. Counterfeit drugs: check combivir, serostim, epogen. AIDS Treat News. 2001; issue 380. http://www.aegis.com/pubs/atn/2002/ATN38003.html. Accessed 24 Jun 2015.
Ravinetto R. Counterfeit ARVs in DRC. E- drug. 2004. http://www.essentialdrugs.org/edrug. Accessed 12 Oct 2016.
Schuman M, Schneider S, Omes C, Wennig R, Fundira L, Tayari JC, Arendt V. HPLC analysis of generic antiretroviral drugs purchased in Rwanda. Bull Soc Sci Méd. 2005;3:317–25.
Oguntibeju OO. Quality of life of people living with HIV and AIDS and antiretroviral therapy. HIV/AIDS (Auckl). 2012;4:117–24.
Candiani TMS, Pinto J, Cardoso CAA, Carvalho IR, Dias ACM, Carneiro M, Goulart EA. Impact of highly active antiretroviral therapy (HA) on the incidence of opportunistic infections, hospitalizations and mortality among children and adolescents living with HIV/AIDS in Belo Horizonte, Minas Gerais State Brazil. Cadernos de Saúde Pública. 2007;23(Suppl 3):S414–23. CrossRefPubMed
Goga AE, Singh Y, Singh M, Noveve N, Magasana V, Ramraj T, Abdullah F, Coovadia AH, Bhardwaj S, Sherman GG. Enhancing HIV treatment access and outcomes amongst HIV infected children and adolescents in resource limited settings. Matern Child Health J. 2016. (Epub ahead of print).
WHO quality assurance and safety medicines policy and standards. Survey of the quality of antiretroviral medicines circulating in selected African Countries; 2007. WHO/PSM/QSM/2007.9.
Comité National de Lutte contre le SIDA. Vers l’accès universel aux traitements et soins en faveur des adultes et enfants vivant avec le VIH/SIDA au Cameroun. Rapport de progrès N°11; 2008.
World Health Organization. Guidelines on packaging for pharmaceutical products. WHO technical report series. Geneva: World Health Organisation; 2002.
WHO Prequalification Programme: Access to quality control laboratories that meet recommended international norms and standards for the analysis of products in the prequalification programme. HIV/AIDS, malaria and tuberculosis products version: 5th ed. 2007. disponible à l’ http://mednet3.who.int/prequal/lists/PQ_QCLabsList.pdf, consulté le 20 janvier 2009.
World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection WHO. Geneva: World Health Organisation; 2013.
Siddiqui MR, AlOthman ZA, Rahman N. Analytical techniques in pharmaceutical analysis: a review. Arabian J. Chem. 2017;10(Suppl 1):S1409–21. CrossRef
Penzack S, Acosta E, Tavel J, Masur H. Analysis of generic Nevirapine products in developing countries. JAMA. 2003;289:2648–9. CrossRef
Phillips AN, Cambiano V, Miners A, Revill P, Pillay D, Lundgren JD, Bennett D, Raizes E, Nakagawa F, De Luca A, Vitoria M, Barcarolo J, Perriens J, Jordan MR, Bertagnolio S. Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis. Lancet HIV. 2014;1(2):e85–93. CrossRefPubMedPubMedCentral
- Antiretroviral therapy supply chain quality control and assurance in improving people living with HIV therapeutic outcomes in Cameroon
M. P. Ngogang Djobet
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II